15811-21-9

Usage

Uses

Used in Pharmaceutical Industry:
Spiro[2.5]octan-6-one is used as a P2X3 inhibitor for treating P2X3 receptor dysfunction diseases. P2X3 receptors are ion channels found in sensory neurons, and their dysfunction has been associated with various pain-related conditions. By inhibiting these receptors, Spiro[2.5]octan-6-one can help alleviate pain and improve the quality of life for patients suffering from such diseases.

Upstream product

• 51656-90-7 8-methylene-1,4-dioxaspiro[4.5]decane 
• 75-11-6 diiodomethane 
• 185-65-9 spiro[2.5]octane 
• 1354932-10-7 9-methylene-1,5-dioxaspiro[5.5]undecane 
• 52875-47-5 7,10-dioxadispiro[2.2.4⁶.2³]dodecane 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Downstream Products

• 1424996-19-9 C₂₉H₃₂N₂O₅S 
• 1424995-28-7 C₁₅H₁₆N₂O₃ 
• 1424995-31-2 C₂₄H₂₃NO₄ 
• 1424995-32-3 C₂₅H₂₅NO₄ 
• 99799-73-2 spiro[2.5]octane-6-amine 
• 1557232-34-4 N-(1-benzyl-1H-pyrazol-4-yl)-1',4',5',7'-tetrahydrospiro[cyclopropane-1,6'-indazole]-3'-carboxamide 
• 1557248-89-1 C₂₆H₃₅N₅O₂Si 
• 1516885-76-9 (S)-N-(3-(2-ethyl-4-(5-(3-ethyl-6,7-dihydro-4H-spiro[benzo[c]thiophene-5,1'-cyclopropan]-1-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 910636-73-6 C₂₃H₂₆O₂S 

Relevant academic research and scientific papers

N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

PYRROLO[2,3-C]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE

Disclosed are a pyrrolo[2,3-c]pyridine derivative, a preparation method therefor, and use thereof in medicine. Specifically, disclosed are a pyrrolo[2,3-c]pyridine derivative as represented by general formula (1), a preparation method therefor, a pharmaceutical composition comprising the derivative, as well as use thereof as a BRD4 inhibitor in the treatment of related diseases such as cancers, inflammations, chronic liver diseases, diabetes, cardiovascular diseases and AIDS, each substituent in general formula (I) being same as defined in the description.

Novel S1P1 receptor agonists - Part 2: From bicyclo[3.1.0] hexane-fused thiophenes to isobutyl substituted thiophenes

Previously, we reported on the discovery of a novel series of bicyclo[3.1.0]hexane fused thiophene derivatives that serve as potent and selective S1P1 receptor agonists. Here, we discuss our efforts to simplify the bicyclohexane fused thiophene

CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

APOPTOSIS INDUCERS

This invention comprises novel compounds which inhibit the activity of anti-apoptotic Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for example, in the treatment of cancer.

HEPATITIS C INHIBITOR COMPOUNDS

A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: X1 and X2 are each independently CRB or N; RB is H, (C1-6)alkyl, (C1-6/sub

MELANOCORTIN RECEPTOR AGONISTS

The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Hydrogenated Benzo (C) Thiophene Derivatives as Immunomodulators

The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS

The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.